Viral diseases cause millions of deaths each year. Although vaccines are a viable solution, they are far from perfect. The process of creating a vaccine is lengthy, expensive, and difficult because each virus requires a specific vaccine and random mutations can harm the vaccine’s effectiveness.
We are developing an antiviral drug that can destroy the target virus at the cellular level without causing harm to the cell or the body.
In addition to our drug, we are changing the way modern medicine combats viral pandemics, from preventive to active treatment.
To cure the world of viral diseases
We at Viritis have developed a new antiviral drug that can destroy pathogenic viruses at the cellular level without harming the cell itself.
Our product is an antiviral drug including our hybrid molecule and nanotechnology delivery mechanism. The molecule and therapeutic method are patentable to our knowledge.
B.Sc. Biotechnology, Entrepreneur, acceleration programs manager, and business development specialist with more than six years of experience as a CEO and founder of several startup companies.
Ph.D. in Molecular Virology and Pathology at the Hebrew University of Jerusalem. Researcher of Genetic Diseases in the Molecular Metabolic Department, Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
Institutional and capital markets finance expert. As an entrepreneur founded and led two financial ventures to successful capitations. Aaron worked for the chief comptroller at the Israeli Ministry of Economics.
Pathogenic viruses are considered a major threat to world population health. The existing solution for viral diseases is antiviral drugs and vaccines, both limited in their therapeutic effects.
We at Viritis Ltd. developed a new anti-viral drug and delivering mechanism that has the ability to fight and hinder pathogenic viruses at the cellular level.
Our solution is intended for all humans who suffer from viral diseases and to target healthcare systems and pharmaceutical companies.
Vaccines are the main and only solution against viral diseases, yet this solution has major shortcomings:
Governments as well as the private sector are investing great sums of money in the development of antiviral drugs and treatments now more than ever.
$300,000 for conducting POC testing and applying for a provisional patent
Contact them directly.